Innoplexus Launches Blockchain Platform to Drive Pharma Innovation

Global AI company Innoplexus launched today a groundbreaking blockchain platform to dramatically increase the amount of data available for drug research and discovery. This new platform—an update to Innoplexus’ flagship product iPlexus—is the first of its kind, and will allow researchers to upload and license unpublished data on the blockchain to facilitate collaboration, reduce duplicative work, and accelerate the pace of innovation. 

The cost of developing new drugs continues to be a major issue in the industry, and the long-term R&D productivity challenge remains to be fixed. One main reason is the high failure rates for investigational compounds. Balancing the risk-reward equation is becoming an increasingly significant factor for pharma: the failure costs of new molecular entities are climbing, which in turn are dramatically raising the overall cost.

iPlexus has provided analytics and insights to hundreds of pharma companies since 2014, using AI technologies and the world’s largest life sciences’ ontology to normalize unstructured data from over 1 trillion data relationships from published journal articles, dissertations, clinical trials, and more. With today’s update, researchers will be able to upload unpublished experimental data from both successful and failed experiments to iPlexus. Insights from these unpublished experiments (especially from unsuccessful experiments) can help pharma companies reduce the time and cost of drug development significantly by avoiding duplicative work. 


For its innovative technology, Innoplexus filed 12 patent applications, and more are in preparation. For a technical overview of the platform and additional details, please download the white paper

Co-founder and CEO of Innoplexus, Gunjan Bhardwaj, shared his vision for the new iPlexus: "We are already in final negotiations with CROs, universities, and pharmaceutical companies, who see the power of this new architecture that provides a 360-degree view, thereby reducing the drug development cycle time. So many useful insights get lost when data from failed experiments go unpublished. Blockchain gives researchers a way to share unpublished data securely for the first time. More sharing of insights and data means more creative research, more successful clinical trials, and faster innovation. The end result is more effective, less expensive drugs for consumers."

Über die Innoplexus AG

Innoplexus AG offers Data as a Service and Continuous Analytics as a Service products and solutions helping organisations move towards continuous decision-making by generating insights from structured and unstructured private and public data leveraging cutting edge Artificial Intelligence and Deep Learning technologies. Founded in 2011, INNOPLEXUS AG is headquartered in Eschborn, Germany with offices in Pune, India, and Hoboken, USA.
Find out more: http://www.innoplexus.com

Firmenkontakt und Herausgeber der Meldung:

Innoplexus AG
Frankfurter Strasse 63
65760 Eschborn
Telefon: +49 (6196) 7774285
http://www.innoplexus.com

Ansprechpartner:
Silke Otte
Marketing und PR
E-Mail: silke.otte@innoplexus.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.